Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension
about
Clinical activity and safety of combination therapy with temsirolimus and bevacizumab for advanced melanoma: a phase II trial (CTEP 7190/Mel47)MicroRNAs induced in melanoma treated with combination targeted therapy of Temsirolimus and BevacizumabBevacizumab-related toxicities in the National Cancer Institute malignant glioma trial cohort.Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysisCorrelation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer.Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.Targeting developmental pathways in children with cancer: what price success?Tumor vasculature: the Achilles' heel of cancer?Angiogenesis inhibitors in cancer therapy: mechanistic perspective on classification and treatment rationales.Vascular permeability and drug delivery in cancers.Emerging growth factor receptor antagonists for the treatment of advanced melanoma.von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans.Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.Role of arterial hypertension as a predictive marker for bevacizumab efficacy in recurrent glioblastoma - a prospective analysis.Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection.Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.
P2860
Q30412106-4AFB34EB-DDE0-4168-8F4B-2349DF517977Q30415894-6177FF90-6A42-44C0-8DCC-7E08F4E665D6Q33416917-B993BF90-7806-4D02-8EC5-92D03E06774BQ33418555-5FD51057-5996-4CC9-9B5F-AB5671E96678Q33770680-EF97A0E9-306F-43F0-91CB-CBE058558EB9Q34455292-CE684871-62E5-4F59-9503-796637AB2E75Q34989562-756B00FE-7BAC-4C9E-B6C4-FD84E45B2A51Q36014062-64187BFA-2B9C-40BF-8F37-B76C7D06A731Q36905620-5256D4A8-F6BF-44D2-B1F1-3603D6FB57F0Q38057420-4456ABEE-C7C5-4A24-A4F4-AFF9727B0E58Q38130312-9E56B2B0-CDC6-457D-BACB-5D0E6CB61585Q38130686-D254E874-D6DF-4FFB-89A2-C6937D2DE89EQ39340696-FEB470AD-DA89-40FD-BC3E-8F74EEB950CBQ40671371-CE8DC263-5C87-41CF-BD8D-268993C55D47Q41492291-E90E7BC6-29AE-4CC8-898D-458635848580Q44103433-E24AB696-CF65-45A5-9DBD-C8F6033E0100Q50041876-D1DAF9EA-4CE0-4335-8814-014FEDDF8DD0Q53142244-C929ED42-1EEF-4CBE-8472-2F47BCFD13C7Q53303141-CCF0E79A-169A-4971-B719-8A5F792F3D3F
P2860
Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Clinical efficacy and safety o ...... of induced early hypertension
@ast
Clinical efficacy and safety o ...... of induced early hypertension
@en
Clinical efficacy and safety o ...... of induced early hypertension
@nl
type
label
Clinical efficacy and safety o ...... of induced early hypertension
@ast
Clinical efficacy and safety o ...... of induced early hypertension
@en
Clinical efficacy and safety o ...... of induced early hypertension
@nl
prefLabel
Clinical efficacy and safety o ...... of induced early hypertension
@ast
Clinical efficacy and safety o ...... of induced early hypertension
@en
Clinical efficacy and safety o ...... of induced early hypertension
@nl
P2093
P2860
P50
P3181
P1433
P1476
Clinical efficacy and safety o ...... of induced early hypertension
@en
P2093
Cornelia Schuster
Daniel Heinrich
Hanne Puntervoll
Hans P Eikesdal
Jürgen Geisler
Oddbjørn Straume
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0038364
P407
P577
2012-01-01T00:00:00Z